Cart
sales@molnova.com
Home - Products - Tyrosine Kinase - CSF1R - Vimseltinib

Vimseltinib

CAS No. 1628606-05-2

Vimseltinib( DCC-3014 )

Catalog No. M26081 CAS No. 1628606-05-2

DCC-3014 is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM) extracted from the patent WO2014145025A2 (Example 10).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 215 In Stock
10MG 340 In Stock
25MG 575 In Stock
50MG 822 In Stock
100MG 1107 In Stock
500MG 2241 In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Vimseltinib
  • Note
    Research use only, not for human use.
  • Brief Description
    DCC-3014 is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM) extracted from the patent WO2014145025A2 (Example 10).
  • Description
    DCC-3014 is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM) extracted from the patent WO2014145025A2 (Example 10).(In Vitro):DCC-3014 has anti-cancer and anti-proliferative activities.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    DCC-3014
  • Pathway
    Tyrosine Kinase
  • Target
    CSF1R
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1628606-05-2
  • Formula Weight
    431.5
  • Molecular Formula
    C23H25N7O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (115.88 mM)
  • SMILES
    CC(C)Nc1ncc(-c2ccc(Oc3ccnc(c3)-c3cnn(C)c3)c(C)n2)c(=O)n1C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Kohno M, et al. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res. 1992 Feb;70(2):241-7.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Mavrilimumab

    Mavrilimumab (CAM 3001) is a monoclonal antibody with antiviral activity that targets the α subunit of the granulocytic-macrophage colony-stimulating factor (GM-CSF) receptor, inhibiting downstream intracellular GM-CSF signaling.

  • Anumigilimab

    Anumigilimab (CSL-324) is a fully human therapeutic anti-G-CSFR antibody with potential anti-tumor activity for the study of inflammation.

  • PLX647

    PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respectively.

Sign In Join Free